 (J Clin Pathol 2001;54:533-538) 
The transcription factor AP-2 was originally identified as a nuclear factor regulating the expression of human metallothionein IIa. 1 AP-2 has also been reported to be involved in the regulation of various genes, including those encoding p21, c-KIT, MCAM (MUC18), type IV collagenase, c-MYC, c-erbB-2, E-cadherin, and the cytokeratins. [2] [3] [4] [5] [6] [7] [8] [9] In addition, AP-2 has a role in the embryonal development of the hindbrain, spinal cord, face, and limbs. 10 Loss of AP-2 gene function can result in severe deformities within tissues of ectodermal origin. 2 The AP-2 family of transcription factors consists of three homologous 50 kDa proteins-AP-2 , AP-2 , and AP-2 -which are encoded by separate genes. 11 The AP-2 , AP-, and AP-genes are located at chromosomes 6p24, 6p12, and 20q13, respectively. 12 The chromosomal location of AP-2 (6p24-22.3) has been reported to be a frequent site for loss of heterozygosity in cancer. [13] [14] [15] [16] AP-2 has also been shown to activate p21 expression, providing a link between diVerentiation and negative cell cycle control. 1 2 However, the mechanisms by which AP-2 is involved in normal development and the regulation of terminal diVerentiation of cells are mostly unknown.
Recently, a decrease in AP-2 immunopositivity has been described in cervical intraepithelial neoplasia. 17 In addition, AP-2 expression was decreased within human malignant melanoma tumours compared with the strongly immunopositive normal adjacent epidermis. 3 In stage I cutaneous malignant melanoma, reduced AP-2 expression correlated with malignant transformation and tumour progression. 18 Similar results have been described in ovarian cancer, in which loss of cytoplasmic AP-2 has been associated with poor survival, 19 and the loss of AP-2 and AP-2 has been associated with disease progression in breast cancer.
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To the best of our knowledge, the expression of AP-2 , AP-2 , and AP-2 has not been studied previously in colorectal carcinomas and adenomas. Therefore, we analysed the expression of AP-2 by in situ hybridisation (ISH) and reverse transcription polymerase chain reaction (RT-PCR); we also analysed AP-2 , AP-2 , and AP-2 proteins by immunohistochemistry (ICH) to compare these methods and to clarify the role of AP-2 expression in colorectal cancer progression.
Methods

PATIENTS
Our study consisted of 30 randomly selected patients diagnosed and treated at Kuopio University Hospital for colorectal adenocarcinoma in 1996 and 13 patients with colorectal adenoma. The clinical staging of all tumours was completed according to the UICC (1997) 20 and modified Dukes's classifications. 21 Table 1 summarises the pertinent data on the patients.
HISTOLOGICAL METHODS
The tumour samples obtained during surgery were immediately fixed in 10% buVered formalin (pH 7.0), and later embedded in paraYn wax. Several original sections from each of the primary tumours were re-examined by two observers unaware of the clinical data or the disease outcome, and the most representative tissue block (the most malignant section of the tumour) was selected, cut at 5 µm thickness, and stained with haematoxylin and eosin (HE). Tumours were graded as well (grade 1), moderately (grade 2), or poorly (grade 3) diVerentiated (WHO grade). In adenomas, dysplasia was graded as mild (1), moderate (2), or severe (3). Table 1 gives the patients' histopathological data.
IHC DETECTION OF AP-2
ParaYn wax embedded sections (5 µm thick) were rehydrated and washed twice for five minutes with phosphate buVered saline (PBS). The sections were heated in a microwave oven in 0.05 mol/litre Tris/HCl buVer (pH 9.7) for two times five minutes. Endogenous peroxidase activity was blocked with 5% H 2 O 2 for five minutes, followed by two washes (five minutes each) with PBS. The tissue sections were incubated overnight at 4°C with a primary antibody. A rabbit polyclonal anti-AP-2 (C-18), anti-AP-(C-20), or anti-AP-(T-17) (Santa Cruz Biotechnology, Santa Cruz, California, USA) antibody was used at a working dilution of 1/1000 for AP-2 , 1/100 for AP-2 , and 1/200 for AP-2 . The slides were incubated with the secondary antibody for 30 minutes and washed twice for five minutes with PBS. The slides were then incubated for 40 minutes in preformed avidin-biotin peroxidase complex (ABC, Vectastain Elite kit; Vector, Burlingame, California, USA) and washed twice for five minutes with PBS. Colour was developed with diaminobenzidine tetrahydrochloride (DAB) (Sigma, St Louis, Missouri, USA). The slides were counterstained with Mayer's haematoxylin, dehydrated, cleared, and mounted with DePex (BDH Limited, Poole, Dorset, UK). A corresponding section processed without the primary antibody was used as a negative control and the inflammatory cells within the tumour served as positive internal controls.
All slides were evaluated with a microscope (field diameter, 490 µm) and the fraction of positive tumour cells was assessed as the percentage of the whole carcinoma or adenoma area by three observers (KMR, JKK, and V-MK) who were unaware of the clinical data of the patients. Discrepancies between the observers were found in less than 10% of the slides examined, and consensus was reached on further review. The cytoplasmic positivity for AP-2 , AP-2 , and AP-2 was recorded. When over 50% positivity in tumour epithelium was noted staining was considered to be diVuse. AP-2 positive nuclei were also evaluated, both in adenomas and carcinomas.
mRNA IN SITU HYBRIDISATION
For ISH, we used sections that were consecutive with those used for ICH. Sections (5 µm thick) were dewaxed in xylene and graded alcohols. The sections were rinsed in 0.85% (2) 7 Severe dysplasia (3) 1
Figure 1 AP-2 immunohistochemical analysis: diVuse cytoplasmic (A) AP-2 , (B) AP-2 , and (C) AP-2 expression in colorectal adenocarcinoma cells. Bar, 60 µm.
NaCl for five minutes and microwaved in 0.01M citrate buVer (pH 6.0) for five minutes. The sections were cooled in the same buVer for 20 minutes and rinsed with PBS for five minutes. The sections were then fixed in 4% paraformaldehyde and rinsed twice in PBS for five minutes. The sections were pretreated with 0.1M HCl for 10 minutes and digested for 20 minutes by proteinase K (Boehringer Mannheim, Mannheim, Germany) at a concentration of 20 µg/ml. After rinsing with PBS and fixation in 4% paraformaldehyde, the sections were dehydrated in a series of graded alcohols and air dried. All sections were then prehybridised for two hours at 62°C. Recombinant plasmid pHAP2-Hsma containing human AP-2 exon 2 (transactivation domain) (kindly donated by Dr Mitchell from the department of biochemistry and molecular biology, Pennsylvania State University, USA) in a pBluescript KS+ vector was linearised to generate antisense and sense digoxigenin labelled probes using the DIG RNA labelling kit (Boehringer Mannheim). Probes were added to the hybridisation buVer at 3.5 ng/µl, and the sections were hybridised overnight at 62°C in a humidified chamber. Subsequently, sections were washed in buVers with increasing stringency (from 2× to 0.2× saline sodium citrate at 57°C). Non-specific binding was blocked with 2% normal sheep serum in Tris buVered saline. Hybridisation signals were detected by incubation overnight in antidigoxigenin alkaline phosphatase conjugate (Boehringer Mannheim) at 1/1000, followed by nitroblue tetrazolium(NBT)/BCIP for one hour. The reaction was stopped by diluting with water and sections were dehydrated and coverslipped with Mountex (Histolab Production AB, Sweden). The sense probe served as a negative control. ISH staining was graded as negative (−), focally positive (+), and diVusely positive (moderate and strong) (+ + and +++).
RT-PCR AMPLIFICATION
For the expression of AP-2 , total cellular RNA was extracted from 20 µm thick paraYn wax embedded tissue sections of the tumour, as described previously by Sugg et al. 22 The RNA was used as a template to synthesise first strand cDNA, and PCR amplification was performed using the enhanced avian RT-PCR kit (Sigma, St Louis, USA). The primers for AP-2 were designed in our laboratory and commercially synthesised (MedProbe, Oslo, Norway). The specific primers used were: 5'-GCCCCGTGTCCCT GTCCAA-3' and 5'-TGAGGAGCGAGA GGCGACC-3'. The PCR conditions were as described in the 
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STATISTICAL ANALYSIS
The SPSS-Win 7.5 program package was used for statistical calculations. The relations between AP-2 , AP-2 , AP-2 , and mRNA were analysed. Each parameter in the analysis was considered as a continuous variable. The interrelations between the categorical IHC and ISH variables and their associations with clinicopathological parameters were examined by contigency tables, which were further analysed by means of 2 tests. In these analyses AP-2 , AP-2 , and AP-2 expression patterns were graded into two groups using 10%, 45%, or 15% cytoplasmic staining positivity in cancer cells as a cut oV point, respectively. These percentages are the 50th centiles in a frequency distribution for AP-2 , AP-2 , and AP-2 . Because only some tumour cell nuclei showed AP-2 positivity no statistical analyses were performed on nuclear staining.
Results
AP-2 PROTEIN EXPRESSION
In immunohistochemical analyses of AP-2 proteins, negative control sections remained negative, and in tumour sections strongly positive inflammatory cells served as internal controls. Mild cytoplasmic expression of AP-2 , AP-2 , and AP-2 was constantly seen in normal colorectal epithelium. Tables 2 and 3 show the AP-2 , AP-2 , and AP-2 expression patterns in colorectal adenocarcinoma (fig 1) and adenoma. Specifically, 18 of 30 adenocarcinomas were positive for AP-2 and 28 of 30 were positive for AP-2 . In six of 30 adenocarcinomas AP-2 expression was diVuse (over 50% positivity). AP-2 positivity was found in 29 of 30 adenocarcinomas and staining was diVuse in 14 of the 30 cases. There was a higher cytoplasmic AP-2 percentage fraction of positive tumour cells in adenomas than in carcinomas. In addition, in adenomas the AP-2 percentage fraction was higher than that of AP-2 or AP-2 (table 3). In four of 30 carcinomas and in three of 13 adenomas some nuclei (<5%) were AP-2 positive (tables 2 and 3).
AP-2 mRNA EXPRESSION AND RT-PCR
Consecutive sections of each specimen, stained by the sense probe, remained negative throughout in ISH. Normal colorectal epithelium was slightly positive and the mRNA signal was seen intracellularly as distinct blue dots. Tables 2  and 3 show the frequency distribution of AP-2 mRNA in colorectal carcinomas and adenomas. AP-2 mRNA was expressed moderately or strongly (++ and +++) in 17 of 30 carcinomas (fig 2) . In adenomas AP-2 mRNA values were generally lower (table 3) (table 2) . In adenomas, six of 13 displayed similar mRNA and protein staining patterns (table 3) . 
Discussion
To date, only a few studies have examined the expression of AP-2 in human tumours. 11 17-19 23 24 Transfection of AP-2 into hepatoblastoma and colon adenocarcinoma cell lines that lack endogenous AP-2 expression has resulted in negative cell cycle control and tumour growth inhibition in vitro. 2 Mild cytoplasmic expression of AP-2 , AP-2 , and AP-2 was consistently seen in normal colorectal epithelium in our study. Our results revealed downregulated cytoplasmic AP-2 expression in high grade and advanced Dukes's stage tumours. In addition, low cytoplasmic AP-2 expression was seen in high grade carcinomas. These findings are in accordance with previous reports in which low AP-2 expression was associated with higher tumour malignancy and poor survival. [17] [18] [19] According to recent studies, AP-2 is a potential new tumour suppressor gene. 2 3 11 18 24 In malignant melanoma and breast cancer reduced nuclear AP-2 has been associated with poor prognosis. 11 18 However, the results shown in our study and in ovarian cancer by Anttila and colleagues 19 suggest that reduced cytoplasmic AP-2 expression also correlates with higher malignant potential. In our series AP-2 expression was seen mainly in the cytoplasm but some nuclear positivity was also detected. AP-2 and AP-2 were expressed only in the cytoplasm of the tumours. Both nuclear and cytoplasmic expression of AP-2 has been observed in ovarian carcinomas, malignant melanomas, cervical intraepithelial neoplasms, and in childhood medulloblastomas, 17-19 23 as well as in our previous series of colorectal adenocarcinomas. 25 The pattern of AP-2 expression may be tumour type specific, because in breast cancer AP-2 seems to be limited to cancer cell nuclei. 11 26 Because it is thought that the nuclear location of a transcription factor is essential for its functions, the mechanisms by which cytoplasmic AP-2 and AP-2 mediate tumour suppression in colorectal cancer are still unknown. There are, however, other transcription factors, such as p53 27 28 and BRCA1, 29 which have also been described in the cytoplasm of cancer cells and have prognostic value.
Our study shows that approximately half of colorectal adenocarcinomas express AP-2 mRNA moderately or strongly. However, in approximately a quarter of cases without AP-2 protein expression the presence of mRNA was detected throughout the entire section. It is possible that in these cases AP-2 mRNA was not adequately translated into protein, either because of impaired posttranscriptional processing of the mRNA transcript, 30 or the repression of translation initiation, which is controlled by specific RNA-protein interactions. 31 32 Alternatively, spliced AP-2 variants 31 or specific translation inhibitory elements 33 34 might function as translational repressors. Another possible explanation is premature truncation of the AP-2 protein, which would aVect antibody aYnity or degradation of the AP-2 protein. Our finding is supported by similar observations in malignant melanoma 35 and in epithelial ovarian carcinoma. 19 A discordance between urokinase (u-PA) and tissue (t-PA) plasminogen activator protein and mRNA values has also been seen in endometrial carcinoma, in which the amount of mRNA for both u-PA and t-PA in cancer tissues was much lower than was expected from the corresponding protein data. Evidently, high tumour tissue concentrations of these proteins did not result from transcriptional regulation, although the reduction of mRNA could indicate downregulation of transcription or possibly reduced mRNA stability. 36 In conclusion, our results revealed reduced AP-2 protein expression in colorectal carcinomas, and that reduced cytoplasmic AP-2 and AP-2 protein expression correlated inversely with colorectal carcinoma malignancy. Adenomas were more often AP-2 positive than carcinomas. Our ISH results also suggest that post-transcriptional events might eVectively downregulate the expression of AP-2 , although the growth suppressive mechanisms of AP-2 still remain largely unknown. In addition, the role of AP-2 in tumour growth is probably tissue specific. Additional studies will be required to clarify the role of transcription factors in cancer progression.
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